SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Idenix Pharmaceuticals (IDIX)
An SI Board Since March 2004
Posts SubjectMarks Bans Symbol
412 15 0 IDIX
Emcee:  michael_f_murphy Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
87My guess would be you're high on cogs unless there's something complicatrkrw-10/25/2006
86<i>Dew doesn't seem to mind the cross-posting of useful, non-inflammatDewDiligence_on_SI-10/25/2006
85We’ll get all the details at Friday’s analyst meeting and 3Q06 CC: biz.yahoo.coDewDiligence_on_SI-10/25/2006
84Of the assumed $500M in US & EU sales, I’m figuring $175M on selling and marDewDiligence_on_SI-10/25/2006
83Not commenting on the $500M projection, but I can say for sure his pretax marginrkrw-10/25/2006
82Dew's telbivudine sales projections . . . Dew doesn't seem to mintuck-10/25/2006
81Congrats Dew. Any launch timing given? JonRobohogs-10/25/2006
80Any personal sales projections for 2007? Strange trade name btw but kind of catcrkrw-10/25/2006
79FDA Approves Tyzeka (aka Telbivudine) biz.yahoo.comDewDiligence_on_SI-10/25/2006
78I’m happy with IDIX trading flat today amid the ITMN-Roche deal. What is the reDewDiligence_on_SI-10/17/2006
77Roche Begins Phase-2 for HCV Polymerase Inhibitor: investorshub.comDewDiligence_on_SI-10/13/2006
76HCV Treatment Paradigms 1989-2015: investorshub.comDewDiligence_on_SI-9/30/2006
75<i>But then I think to myself that IDIX and the FDA may have been aware ofDewDiligence_on_SI-9/27/2006
74[Ribavirin Antagonizes Valopicitabine: implications when planning clinical studituck-9/27/2006
73Telbivudine should do OK. It will likely be priced to undersell Baraclude and itDewDiligence_on_SI-9/27/2006
72I did get back into IDIX a couple of days ago, so that's nice to see. I woutuck-9/27/2006
71Bullish news from UBS webcast: investorshub.com investorshub.comDewDiligence_on_SI-9/27/2006
70Telbivudine Approved in Switzerland for Chronic Hepatitis B: investorshub.com DewDiligence_on_SI-9/21/2006
69Webcast notes from Bear Stearns: investorshub.comDewDiligence_on_SI-9/11/2006
68Notes from today’s (uneventful) Weisel webcast: investorshub.comDewDiligence_on_SI-9/7/2006
67VPHM and WYE Report Preliminary Phase-1b Combination Data in HCV: investorshub.DewDiligence_on_SI-8/28/2006
66For my own records and whoever's . . . the Telbivudine PDUFA date is Octtuck-8/28/2006
65October is the big month (Telbivudine PDUFA date and AASLD)—probably not much ofDewDiligence_on_SI-8/28/2006
64Yes, I have a long position, on which I am slightly ahead, and I may add on weaktuck-8/28/2006
63FWIW: investorshub.comDewDiligence_on_SI-8/27/2006
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News